Introduction：Basic information about 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE CAS 321-64-2, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Table of Contents
- 1. 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Basic information
- 2. 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Chemical Properties
- 3. Safety Information
- 4. 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Usage And Synthesis
- 5. 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Preparation Products And Raw materials
1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Basic information
| Product Name: | 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE |
| Synonyms: | 1,2,3,4-Tetrahydro-5-aminoacridine;1,2,3,4-tetrahydro-9-acridinamin;1,2,3,4-tetrahydro-9-amino-acridin;1,2,3,4-Tetrahydro-9-aminoacridine;5-Amino-6,7,8,9-tetrahydroacridine;Acridine, 1,2,3,4-tetrahydro-9-amino-;Acridine, 9-amino-1,2,3,4-tetrahydro-;Acridine, 9-aminotetrahydro- |
| CAS: | 321-64-2 |
| MF: | C13H14N2 |
| MW: | 198.26 |
| EINECS: | 206-291-2 |
| Product Categories: | |
| Mol File: | 321-64-2.mol |
|
1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Chemical Properties
| Melting point | 183.5℃ |
| Boiling point | 325.59°C (rough estimate) |
| density | 0.9827 (rough estimate) |
| refractive index | 1.4400 (estimate) |
| storage temp. | 4°C, away from moisture and light |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 9?+-.0.20(Predicted) |
| color | White to Pale Yellow |
| CAS DataBase Reference | 321-64-2(CAS DataBase Reference) |
Safety Information
1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Usage And Synthesis
| Description | In the 1950s, tacrine was used experimentally to reversecholinergic coma in animals. In the 1960s, tacrine was used toreverse the effects of phencyclidine-like drugs. It was alsomarketed for many years as a respiratory stimulant. In 1993,the US Food and Drug Administration approved tacrine for thetreatment of symptoms of mild to moderate Alzheimer’sdisease. |
| Uses | The current use of tacrine is limited due to its poor oralbioavailability, the necessity for four daily doses, and seriousside effects (including nausea, vomiting, dry mouth, indigestion,diarrhea, loss of appetite, urinary incontinence, collapse,convulsions, and hepatotoxicity). Currently, newer cholinesteraseinhibitors (such as donepezil, rivastigmine, and galantamine)are preferred over tacrine. |
| Definition | ChEBI: Tacrine is a member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor. It is a member of acridines and an aromatic amine. It is a conjugate base of a tacrine(1+). |
| Synthesis Reference(s) | Tetrahedron Letters, 4, p. 1277, 1963 DOI: 10.1039/jr9630005127 |
| Toxicity evaluation | Tacrine has numerous mechanisms of action. The putativeprincipal mechanism of action of tacrine for Alzheimer’sdisease is reversible inhibition of acetylcholinesterase (AChE),which thereby slows the breakdown of the chemical messengeracetylcholine (ACh) in the brain. Tacrine also inhibits butyrylcholinesteraseactivity. In addition, tacrine blocks sodiumand potassium channels. Tacrine also acts as a histamineN-methyltransferase inhibitor.
At a therapeutic dose, tacrine causes liver toxicity. Cytotoxicitystudies using the human liver cell line HepG2 showed thata therapeutic blood concentration of tacrine induces reactiveoxygen species production and glutathione depletion, suggestingthat oxidative stress might be involved in tacrinehepatotoxicity. |
1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE Preparation Products And Raw materials
| Raw materials | Hydroxylamine hydrochloride-->Glycine-->Sodium acetate trihydrate-->Cyclohexanone-->Isatin-->Chloral hydrate-->2-Aminobenzonitrile-->ISATIN-3-OXIME-->Dexecadotril-->9(10H)-Acridinimine-->9,10-dihydroacridin-9-amine-->9-Acridinamine, tetradecahydro- |
